Alphagan, Mirvaso(brimonidine)
Alphagan P, Combigan, Lumify, Mirvaso, Qoliana, Simbrinza (brimonidine) is a small molecule pharmaceutical. Brimonidine was first approved as Alphagan on 1996-09-06. It is used to treat open-angle glaucoma in the USA. It has been approved in Europe to treat ocular hypertension, open-angle glaucoma, and skin diseases. The pharmaceutical is active against alpha-2B adrenergic receptor, alpha-2C adrenergic receptor, and alpha-2A adrenergic receptor.
Download report
Favorite
Novartis Pharmaceuticals
Commercial
Trade Name
FDA
EMA
Alphagan p, Lumify, Mirvaso, Qoliana (generic drugs available since 2003-05-28, discontinued: Alphagan)
CombinationsCombigan, Simbrinza (generic drugs available since 2003-05-28)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Brimonidine tartrate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| ALPHAGAN P | AbbVie | N-021262 RX | 2001-03-16 | 1 products, RLD, RS |
| ALPHAGAN P | AbbVie | N-021770 RX | 2005-08-19 | 1 products, RLD, RS |
| LUMIFY | Bausch Health Companies | N-208144 OTC | 2017-12-22 | 1 products, RLD, RS |
| MIRVASO | Galderma | N-204708 RX | 2013-08-23 | 1 products, RLD, RS |
| QOLIANA | Sandoz | N-021764 RX | 2006-05-22 | 1 products, RLD, RS |
Show 2 discontinued
Brimonidine tartrate
+
Brinzolamide
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| SIMBRINZA | Alcon Research | N-204251 RX | 2013-04-19 | 1 products, RLD, RS |
Brimonidine tartrate
+
Timolol maleate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| COMBIGAN | AbbVie | N-021398 RX | 2007-10-30 | 1 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| alphagan p | New Drug Application | 2013-09-01 |
| combigan | New Drug Application | 2015-10-01 |
| lumify redness reliever eye drops | New Drug Application | 2020-12-16 |
| mirvaso | New Drug Application | 2018-06-27 |
| simbrinza | New Drug Application | 2022-12-16 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| open-angle glaucoma | EFO_0004190 | D005902 | H40.1 |
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Brimonidine Tartrate, Mirvaso, Galderma Labs Lp | |||
| 8053427 | 2031-06-13 | DP | U-1428 |
| 8163725 | 2031-06-13 | DP | |
| 10201517 | 2031-06-13 | DP | |
| 8513247 | 2031-03-25 | DP | U-1428 |
| 8513249 | 2031-03-25 | DP | U-1428 |
| 9861631 | 2031-03-25 | U-1428 | |
| 9861632 | 2031-03-25 | U-1428 | |
| 7439241 | 2025-08-25 | U-1428 | |
| 8231885 | 2025-05-24 | DP | |
| 8410102 | 2025-05-24 | U-1428 | |
| 8426410 | 2025-05-24 | U-1428 | |
| 8859551 | 2024-05-25 | U-1428 | |
| Brimonidine Tartrate / Brinzolamide, Simbrinza, Alcon Labs Inc | |||
| 9044484 | 2030-10-30 | DP | |
| 9421265 | 2030-06-17 | DP | |
| Brimonidine Tartrate, Lumify, Bausch And Lomb Inc | |||
| 8293742 | 2030-07-14 | U-2222 | |
| 9259425 | 2030-07-14 | U-2222 | |
| 11596600 | 2029-07-27 | U-2222 | |
| Brimonidine Tartrate, Qoliana, Sandoz | |||
| 7265117 | 2025-08-19 | DP | |
| Brimonidine Tartrate, Alphagan P, Abbvie | |||
| 8858961 | 2023-09-02 | DP | |
ATC Codes
D: Dermatologicals
— D11: Other dermatological preparations in atc
— D11A: Other dermatological preparations in atc
— D11AX: Other dermatological preparations in atc
— D11AX21: Brimonidine
S: Sensory organ drugs
— S01: Ophthalmologicals
— S01E: Antiglaucoma preparations and miotics
— S01EA: Sympathomimetics in glaucoma therapy
— S01EA05: Brimonidine
— S01G: Decongestants and antiallergics
— S01GA: Sympathomimetics used as decongestants
— S01GA07: Brimonidine
HCPCS
No data
Clinical
Clinical Trials
153 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Ocular hypertension | D009798 | EFO_1001069 | H40.0 | 1 | 5 | 19 | 20 | 6 | 51 |
| Open-angle glaucoma | D005902 | EFO_0004190 | H40.1 | — | 5 | 12 | 17 | 2 | 36 |
| Glaucoma | D005901 | EFO_0000516 | H40 | — | 2 | 7 | 19 | 8 | 36 |
| Rosacea | D012393 | L71 | — | — | 3 | 4 | 2 | 9 | |
| Intraocular pressure | D007429 | 1 | — | — | 1 | 4 | 6 | ||
| Low tension glaucoma | D057066 | EFO_1001022 | H40.12 | — | — | — | 3 | — | 3 |
| Ocular physiological phenomena | D009799 | — | — | — | 1 | 2 | 3 | ||
| Capsule opacification | D058442 | H26.4 | — | — | — | 1 | — | 1 | |
| Relapsing-remitting multiple sclerosis | D020529 | EFO_0003929 | — | — | — | 1 | — | 1 | |
| Prostatic neoplasms | D011471 | C61 | — | — | — | 1 | — | 1 |
Show 6 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Presbyopia | D011305 | H52.4 | 3 | 2 | 2 | — | — | 7 | |
| Eye diseases | D005128 | EFO_0003966 | H44 | — | 2 | 1 | — | 1 | 4 |
| Diabetic retinopathy | D003930 | EFO_0003770 | — | 3 | 1 | — | — | 3 | |
| Dry eye syndromes | D015352 | H04.12 | 1 | 2 | 1 | — | — | 3 | |
| Hyperemia | D006940 | EFO_0003822 | H34.82 | 1 | — | 2 | — | — | 3 |
| Allergic conjunctivitis | D003233 | EFO_0007141 | H10.44 | — | 1 | 2 | — | — | 3 |
| Refractive errors | D012030 | EFO_0003908 | H52.7 | — | 2 | 1 | — | — | 3 |
| Erythema | D004890 | HP_0010783 | L53.9 | — | — | 1 | — | 1 | 2 |
| Miosis | D015877 | HP_0000616 | H57.03 | — | 1 | 1 | — | — | 2 |
| Graft vs host disease | D006086 | D89.81 | — | — | 1 | — | — | 1 |
Show 3 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Macular degeneration | D008268 | EFO_0001365 | H35.30 | — | 4 | — | — | — | 4 |
| Healthy volunteers/patients | — | — | 1 | — | — | 1 | 2 | ||
| Macular edema | D008269 | — | 1 | — | — | — | 1 | ||
| Hand-foot syndrome | D060831 | EFO_1001893 | — | 1 | — | — | — | 1 | |
| Meibomian gland dysfunction | D000080343 | H02.88 | 1 | 1 | — | — | — | 1 | |
| Geographic atrophy | D057092 | — | 1 | — | — | — | 1 | ||
| Retinitis pigmentosa | D012174 | HP_0000580 | H35.52 | 1 | 1 | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cataract | D002386 | EFO_0001059 | H26.9 | — | — | — | — | 2 | 2 |
| Hemorrhage | D006470 | MP_0001914 | R58 | — | — | — | — | 2 | 2 |
| Exfoliation syndrome | D017889 | EFO_0004235 | — | — | — | — | 1 | 1 | |
| Pterygium | D011625 | H11.0 | — | — | — | — | 1 | 1 | |
| Coronavirus | D017934 | — | — | — | — | 1 | 1 | ||
| Hemophilia a | D006467 | EFO_0007267 | D66 | — | — | — | — | 1 | 1 |
| Ventricular dysfunction | D018754 | — | — | — | — | 1 | 1 | ||
| Atrial heart septal defects | D006344 | EFO_1000825 | Q21.1 | — | — | — | — | 1 | 1 |
| Pericardial effusion | D010490 | EFO_0007298 | I31.39 | — | — | — | — | 1 | 1 |
| Diabetes complications | D048909 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | BRIMONIDINE |
| INN | brimonidine |
| Description | Brimonidine is a quinoxaline derivative, a secondary amine and a member of imidazoles. It has a role as an adrenergic agonist, an antihypertensive agent and an alpha-adrenergic agonist. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | Brc1c(NC2=NCCN2)ccc2nccnc12 |
Identifiers
| PDB | — |
| CAS-ID | 59803-98-4 |
| RxCUI | 134615 |
| ChEMBL ID | CHEMBL844 |
| ChEBI ID | 3175 |
| PubChem CID | 2435 |
| DrugBank | DB00484 |
| UNII ID | E6GNX3HHTE (ChemIDplus, GSRS) |
Target
Agency Approved
ADRA2B
ADRA2B
ADRA2C
ADRA2C
ADRA2A
ADRA2A
Organism
Homo sapiens
Gene name
ADRA2B
Gene synonyms
ADRA2L1, ADRA2RL1
NCBI Gene ID
Protein name
alpha-2B adrenergic receptor
Protein synonyms
ADRA2B adrenergic, alpha-2B-, receptor, Alpha-2 adrenergic receptor subtype C2, alpha-2-adrenergic receptor-like 1, Alpha-2B adrenoceptor, Alpha-2B adrenoreceptor, Alpha-2BAR, G-protein coupled receptor
Uniprot ID
Mouse ortholog
Adra2b (11552)
alpha-2B adrenergic receptor (P30545)
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 3,714 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
6,533 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more